Abstract
OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.
| Original language | English |
|---|---|
| Pages (from-to) | 1382-1388 |
| Number of pages | 7 |
| Journal | BJU International |
| Volume | 106 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 1 2010 |
Fingerprint
Keywords
- α-adrenergic receptor
- antagonist
- BPH
- cetrorelix
- growth factors
- LHRH
ASJC Scopus subject areas
- Urology
Cite this
Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. / Siejka, Agnieszka; Schally, Andrew V; Block, Norman L; Barabutis, Nektarios.
In: BJU International, Vol. 106, No. 9, 01.11.2010, p. 1382-1388.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix
AU - Siejka, Agnieszka
AU - Schally, Andrew V
AU - Block, Norman L
AU - Barabutis, Nektarios
PY - 2010/11/1
Y1 - 2010/11/1
N2 - OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.
AB - OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.
KW - α-adrenergic receptor
KW - antagonist
KW - BPH
KW - cetrorelix
KW - growth factors
KW - LHRH
UR - http://www.scopus.com/inward/record.url?scp=77954398049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954398049&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.2010.09215.x
DO - 10.1111/j.1464-410X.2010.09215.x
M3 - Article
C2 - 20151966
AN - SCOPUS:77954398049
VL - 106
SP - 1382
EP - 1388
JO - BJU International
JF - BJU International
SN - 1464-4096
IS - 9
ER -